Αποτελέσματα Αναζήτησης
10 Ιαν 2024 · The purpose of this guideline is to provide expert guidance on the systemic treatment of metastatic breast cancer (MBC) to clinicians, public health leaders, patients, and policymakers in resource-constrained settings.
Clinical practice guidelines serve as a guide for doctors and outline appropriate methods of treatment and care. Guidelines can address specific clinical situations (disease-oriented) or use of approved medical products, procedures, or tests (modality-oriented).
PURPOSE To guide clinicians and policymakers in three global resource-constrained settings on treating patients with metastatic breast cancer (MBC) when Maximal setting–guideline recommended treatment is unavailable. METHODS Amultidisciplinary,multinationalpanelreviewedexistingASCOguidelines
Systemic Treatment of Patients With Metastatic Breast Cancer Resource–Stratified Guideline January 10, 2024 Germline Testing in Patients With Breast Cancer: ASCO–Society of Surgical Oncology Guideline
This flow sheet is derived from recommendations in the 2012 Update of the Breast Cancer Follow-Up & Management Guideline in the Adjuvant Setting. This flow sheet is a practice tool based on ASCO® practice guidelines and is not intended to substitute for the independent professional judgment of the treating physician.
SELECTION OF OPTIMAL ADJUVANT CHEMOTHERAPY AND TARGETED THERAPY FOR EARLY BREAST CANCER: ASCO CLINICAL PRACTICE GUIDELINE FOCUSED UPDATE Recommendation Evidence Rating Patients with early-stage HER2-negative breast cancer with pathologic invasive residual disease at
This guideline covers the management of patients with HER2-positive breast cancer and brain metastases.1. The guideline is meant to provide recommendations specific to patients with HER2-positive disease, in whom the overall prognosis after diagnosis of brain metastases and treatment can be more favorable.
